Allegiance Equity Corporation: PCT Patent Approved for CinGx(TM) to Treat and Prevent Diabetes, Alzheimer's and Dementias

Allegiance Equity Corporation (TSX VENTURE:ANQ) - 

CinGx(TM) and Type 3 Diabetes

There is currently no cure for Diabetes, Alzheimer's, and Dementias but they can
be treated and prevented. Allegiance Equity developed CinGx(TM) as a safe and
effective treatment for these diseases. The incidence of these diseases and
associated costs continue to soar out of control and afflict the world-wide
population. Current treatments are not satisfactory and many have side effects.


CinGx(TM) controls glucose metabolism improves brain function and a healthy
cognitive system. It contains two purified and concentrated natural extracts
that act synergistically to control glucose metabolism, improve brain function,
and minimize the risk of developing dementia, Alzheimer's and diabetes.


CinGx(TM) is effective against recently discovered 'type 3' diabetes resulting
from lower than normal levels of newly detected brain insulin, causing
Alzheimer's disease. Diabetes increases the risk of Alzheimer's disease by up to
65%.


CinGx(TM) is a natural proprietary OTC food additive and meets regulatory
requirements in North America.


Health Benefits of CinGx(TM) include



  Reduces Blood Sugar                Reduces Cholesterol      
  Reduces Triglycerides              Improves Memory          
  Improves Cognitive Function        Improves Energy          
  Improves Mental Well Being                                  
  Anti-Oxidant for Anti-Aging                                 



CinGx(TM) AN EVOLUTION ON FUNCTIONAL FOODS

CinGx(TM) provides exciting new Health Benefits in a multitude of food products
resulting in distinct competitive advantages of




--  Increase demand 
--  Higher Prices 
--  Increased Margins and Profits 



Applications include beverages, coffee, tea, sweeteners, diet foods, meal
replacement, yogurt vitamins and diabetic products etc.


Demand for functional foods with proven Health Benefits is the fastest growing
sector of the food industry.


Several manufacturers have developed new products containing CinGx(TM) to market.

Patent Approvals CinGx(TM)

International Patent Applications have been issued and published for CinGx(TM)
recognizing the health claims for TYPE 3 DIABETES.


About Allegiance

Allegiance develops IP for dermatology, diabetic, and related cardiovascular
central nervous diseases where existing products fail to meet the needs of
patients. And obtains regulatory approval in North America markets.


Allegiance is licensing its extensive portfolio of regulatory approvals and
patents internationally.

(TSXV:ANQ)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024